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Abstract: Obesity is an emerging disease worldwide. Changes in living habits, especially with 
increased consumption of high-calorie foods and decreased levels of physical activity, lead to 
an energy imbalance that brings weight gain. Overweight and obesity are major risk factors 
for several chronic diseases (including cardiovascular diseases, diabetes, and cancer), reduce 
quality of life, and are associated with higher mortality. For all these reasons, it is of the utmost 
importance that the trend be reversed and obese people enabled to lose weight. It is known that 
eating a healthy diet and exercising regularly can help prevent obesity, but data show that in 
many cases these steps are not enough. This is the reason why, over the last few decades, several 
antiobesity drugs have been developed. However, the disappointing results demonstrated for 
the vast majority of them have not discouraged the pharmaceutical industry from continuing 
to look for an effective drug or combination of drugs. The systematic review presented here 
focuses on naltrexone sustained-release/bupropion sustained-release combination (Contrave®). 
We conclude from the current published reports that its effectiveness in the treatment of obesity 
can be estimated as a placebo-subtracted weight loss of around 4.5%. This weight reduction is 
moderate but similar to other antiobesity drugs. The safety profile of this combination is accept-
able, despite additional data regarding cardiovascular disease being needed.
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Background
“Obesity”, defined as a body mass index (BMI) of $30 kg/m2, is an emergent chronic 
disease across the world. Based on the latest estimates, in European Union countries, 
overweight affects 30%–70% of adults and obesity affects 10%–30% of adults. Data 
from the National Health and Nutrition Examination Survey show that in the USA 
more than one-third of adults and almost 17% of children and adolescents were obese 
in 2009–20101 and linear time trend forecasts suggest that, by 2030, 51% of the popula-
tion will be obese.2 Moreover, the estimated annual medical cost of obesity in the USA 
was US$147 billion in 2008.3 This is due in part to the higher morbidity associated 
with obesity in hypertension, type 2 diabetes, coronary heart disease, stroke, gall-
bladder disease, osteoarthritis, sleep apnea, and some types of cancer (endometrial, 
breast, prostate, and colon). Obesity is also associated with pregnancy complications, 
menstrual irregularities, hirsutism, stress incontinence, and psychological disorders 
(depression).4 Mortality increases progressively once the overweight threshold is 
crossed.5 The dramatic increase in obesity prevalence during the past years has turned 
this disorder into a major health problem and prompted authorities to take action to 
decrease the impact of its consequences.





Traditional treatments based on lifestyle modification by 
changing patterns of diet and increasing physical activity are 
usually the first and basic steps in obesity treatment, but, in 
most cases, these only produce short-term weight loss. That 
fact reflects the necessity for other therapeutic strategies, 
such as antiobesity drugs or bariatric surgery.
The ideal antiobesity drug would produce sustained 
weight loss with minimal side effects and may account 
for different mechanisms of action: appetite suppression, 
including eating behavior and food intake; interference with 
nutrient absorption; or increases in metabolism and energy 
expenditure. However, the mechanisms that regulate energy 
balance have a substantial overlap with other physiological 
functions and are influenced by social, hedonic, and psycho-
logical factors that limit the effectiveness of pharmacological 
interventions. It is not therefore surprising that antiobesity 
drug-discovery programs have finished with failures in clini-
cal development and withdrawals due to adverse effects.
Recent improvements in the understanding of peptidergic 
signaling of hunger and satiety from the gastrointestinal 
tract mediated by ghrelin, cholecystokinin, peptide YY, 
and glucagon-like peptide-1 (GLP-1) and of homeostatic 
mechanisms related to leptin and its upstream pathways in the 
hypothalamus have opened up new possibilities.6 Although 
some peptidergic signalers and homeostatic mechanisms have 
now reached clinical development, it is uncertain whether 
they will satisfy all the requirements to be an effective anti-
obesity drug.7
At present, orlistat, an intestinal lipase inhibitor, is 
the only long-term antiobesity drug approved by both the 
European Medicines Agency and the US Food and Drug 
 Administration (FDA) in the USA.8 Phentermine, diethyl-
propion  (amfepramone), benzphetamine, and phendimetra-
zine, all of them amphetamine-like analogs that increase the 
release of norepinephrine, are also approved in the USA as 
antiobesity agents for the short-term treatment of obesity. 
In Europe, phentermine was withdrawn in 1999 and the 
others have never been approved. Lorcaserin (Belviq®; 
Arena Pharmaceuticals, Zofingen, Switzerland) a 5-HT
2C
 
receptor agonist, was also approved by the FDA in 2012 
after being re-filed.7
In other therapeutic fields, such as diabetes and hyper-
tension, lower doses of multiple agents targeting different 
pathways often yield better results than strategies that modify 
one pathway alone. Some combination approaches using two 
kinds of molecules have now reached clinical trial (Table 1) 
and one of them, qnexa (Qsymia®; Vivus, Mountain View, 
CA, USA), a combination of phentermine and topiramate 
sustained-release (SR), has already been approved by the 
FDA. Nevertheless, body-weight control achieved using these 
drugs is far from the sustained weight loss and its consequent 
amelioration of comorbidities following any of the bariatric 
surgical procedures.9
This review focuses on current treatment with the 
combination of naltrexone/bupropion SR (Contrave®; 
Orexigen Therapeutics, La Jolla, CA, USA) that was turned 
down by the FDA owing to potential cardiovascular risk. 
Nevertheless, it seems probable that it will be re-filed in the 
near future when the randomized, double-blind, placebo-
controlled Light Study assesses the actual risk of major 
cardiovascular events. The final decision is expected by the 
end of 2014 based on the interim analysis, although the study 
will not really finish until 2017.
Methods
A systematic search strategy was developed to identify 
publications in both MEDLINE® (National Library of 
Medicine, Bethesda, MD) and the Cochrane library (The 
Cochrane Collaboration, Oxford, UK). The terms “obesity”, 
“ naltrexone”, “bupropion”, and “Contrave” were incorpo-
rated into an electronic search strategy. We were able to find 
44 manuscripts. Twenty of these were general revisions about 
obesity treatment or an update on antiobesity drugs that 
included or mentioned naltrexone or bupropion.6,8–26 The rest 
(24 of them) were about the combination of naltrexone and 
bupropion. One of them was exclusively in rodent models27 
and the rest were mainly in humans28–50 in the form of reviews, 
letters, editorials, posters, or original articles of the clinical 
trials performed to test this combined drug. We comment on 
the most relevant in the present review.
Central nervous system appetite 
and satiety pathways at a glance
The central mechanisms of hunger and satiety are regu-
lated by the arcuate nucleus of the hypothalamus, which 
receives signals by several hormones and peptides synthe-
sized mainly by the gut and adipose tissue, like insulin, 
leptin, ghrelin, peptide PYY, cholecystokinin, GLP-1, and 
others.51
The arcuate nucleus is divided into a lateral and a medial 
portion which work in opposite pathways but transmit signals 
to the same areas of the brain.28 The lateral neurons synthe-
size and secrete neuropeptide Y and Agouti-related protein, 
with orexigenic actions, while medial neurons produce pro-
opiomelanocortin (POMC)44 and cocaine and amphetamine-
regulated transcript that induce anorexigenic actions. POMC 
Drug Design, Development and Therapy 2014:8
Table 1 Antiobesity drugs in development
Name or code Mechanism of action Current status
Monotherapy
 Lorcaserin 5-HT2C receptor agonist FDA approved 2012
 Cetilistat Pancreatic lipase inhibitor NDA filed in Japan
 Liraglutide Long-acting GLP-1 analog Phase iii ongoing
 velneperit Neuropeptide Y5 subtype receptor antagonist Phase ii completed
 JNJ-16269110 MTP inhibitor Phase ii completed
 TTP-435 AgRP inhibitors Phase ii completed
 Beloranib MetAP-2 inhibitor Phase ii ongoing
 Oxyntomodulin Dual agonist of GLP1R and GCGR Phase ii ongoing
 GSK1521498 μ-opioid inverse agonist Phase i completed
 GSK598809 Dopamine D3 receptor antagonist Phase i completed
 PF-04971729 Selective inhibitor of the sodium-dependent  
glucose co-transporter 2
Phase i completed
 PF-04620110 Selective DGAT-1 inhibitor Phase i completed
 LY377604 Selective β3 adrenergic receptor agonist Clinical trial terminated (discontinued?)  
due to results from recent nonclinical 
studies
 Betahistine Histamine subtype receptor H1 agonist  
and H3 subtype receptor antagonist
Failure because of inconsistent results
 Taranabant Cannabinoid receptor inverse agonist Failure because of psychiatric side effects
 MK-0493 Melanocortin receptor 4 Failure because of limited efficacy
Combination
 Phentermine/topiramate Amphetamine derivative FDA approved 2012
  Zonisamide/bupropion (empatic™) CA inhibitor/dopamine  
and noradrenaline reuptake inhibitor
Phase ii completed
 Tesofensine Triple monoamine reuptake inhibitor Phase iii ongoing
  Bupropion/naltrexone (Contrave®) Dopamine and noradrenaline reuptake  
inhibitor/μ-opioid receptor agonist
Phase iii ongoing
 Dov21947 Triple monoamine reuptake inhibitor Phase ii
 Obinepitide Neuropeptide Y2 + Y4 subtype receptor  
agonist
Phase ii: failure for unknown reasons
 Pramlintide/metreleptin Amylin analog/leptin analog Phase ii: failure for commercial reasons
Abbreviations: 5-HT, 5-hydroxytryptamine; AgRP, Agouti-related protein; β3, beta-3; CA, carbonic anhydrase; DGAT-1, diglyceride acyl transferase 1; FDA, US Food and 
Drug Administration; GCGR, glucagon receptor gene; GLP-1, glucagon-like peptide 1; GLP1R, glucagon-like peptide i receptor; μ, mu; MetAP-2, methionine aminopeptidase 2; 
MTP, microsomal triglyceride transfer protein; NDA, non-disclosure agreement.
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is rapidly cleaved into α-MSH and β-endorphin. α-MSH acts 
at melanocortin MC3 and MC4 receptors in the hypothalamus 
and the rest of the brain, inducing satiety and inhibiting food 
intake, as well as increasing resting energy expenditure. On 
the other hand, β-endorphin, an endogenous opioid, autoin-
hibits the POMC pathway, and its excess in rodents leads to 
increased food intake.28
At fasting state, ghrelin, the only peripheral orexigenic 
peptide, stimulates the lateral neurons of the arcuate nucleus 
and initiates food intake; by contrast, at postprandial state, 
all the other mentioned peripheral hormones and peptides 
stimulate the medial arcuate nucleus. From both sides of the 
arcuate nucleus, axons emerge to other hypothalamus parts 
such as paraventricular nucleus, lateral hypothalamus, and 
perifornical area. From them, more complicated pathways, 
still under investigation, pass through the nucleus of the 
solitary tract to the vagus nerve and the superior cervical 
ganglion returning the input to gut to inhibit mechanical and 
secretional stimuli and to close the loop (Figure 1).
Bupropion
“Bupropion” is a dopamine and norepinephrine reuptake 
inhibitor mainly used for the treatment of depression and as 
an aid in smoking cessation.26 Many clinical observations 
have been made indicating that bupropion has an anorexigenic 
activity which has been related to the stimulation of POMC-
producing neurons in the arcuate nucleus of the hypothalamus. 
These neurons release α-MSH, which acts on MC4 receptors, 
decreasing food intake and increasing energy expenditure.30 
The effect of bupropion on POMC-producing neurons has 
been shown in animal models,28 while some clinical studies52,53 
have displayed a modest weight reduction effect of bupropion 
in monotherapy, and, for that reason, it did not meet FDA 
criteria for approval as a monotherapy for obesity.





As mentioned, POMC-producing neurons also release 
beta-endorphin which has an autoinhibitory feedback and 
decreases the anorexigenic effect of α-MSH. This autoin-
hibitory mechanism may disturb the anorexigenic effect of 
α-MSH and might contribute to the limited antiobesity effect 
of bupropion in monotherapy.44
Naltrexone
“Naltrexone” is an opioid receptor antagonist mainly used 
in the treatment of alcohol and opioid addictions.54 It is 
metabolized by the hepatic enzyme dihydrodiol dehydro-
genase to its active metabolite 6β-naltrexol. Both naltrex-
one and 6β-naltrexol are competitive antagonists at the 
μ- and κ-opioid receptors in the central nervous system.55 
In 1979, the observation that naloxone, another opioid 
receptor antagonist, produced a significant reduction in 
short-term food intake in rats proved the role of this kind 
of drug in eating behavior.56 Subsequent studies led to the 
“opioid-palatability hypothesis”, which suggests that opioid 
release plays an important role in the expression of food 
palatability57 and may decrease sweet food pleasantness.58 
Given these observations, naltrexone was seen as a potential 
obesity treatment and several studies have been performed 
and published since the early 1980s. However, the results 
of these studies59–64 were disappointing, because naltrexone 
monotherapy was associated with minimal or no weight 
loss.29 The limited efficacy of a single obesity agent such 
as naltrexone might be explained because of the various 
different mechanisms regulating caloric intake and body 




“Contrave” is a fixed-dose combination of naltrexone and 
bupropion. The idea of associating an antagonist of the opi-
oid receptors, in order to block the autoinhibitory feedback, 
arises as a good way to enhance the anorexigenic effect of 
bupropion. The effect of the combination is synergistic, and 
































Figure 1 Central and peripheral mechanisms of appetite and satiety and site of action of bupropion and naltrexone.
Abbreviations: α-MSH, α-melanocyte-stimulating hormone; AgRP, Agouti-related protein; β-eND, β-endorphin; BUP, bupropion; CART, cocaine and amphetamine-regulated 
transcript; CCK, cholecystokinin; CNS, central nervous system; GLP-1, glucagon-like peptide-1; NAL, naltrexone; NPY, neuropeptide Y; POMC, pro-opiomelanocortin; 
PP, pancreatic polypeptide; PYY, peptide YY.
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studies.28 Blunting the hypothalamic reactivity to food cues 
while enhancing the activation of regions involved in self-
control and internal awareness might underlie its therapeutic 
benefits in obesity.50
Preclinical studies
In vitro electrophysiological studies in mouse brain slices 
have demonstrated the stimulatory effect of bupropion and 
naltrexone, independently, over the POMC neurons. When 
a combination of these two drugs was used, the stimulatory 
effect was greater.28 In the same publication, an in vivo study 
in obese mice showed a significant reduction in food intake 
when a combination of bupropion and naltrexone was used, in 
front of the moderate effect observed when these drugs were 
administered independently. These observations strongly 
support the hypothesis of a synergic anorexigenic effect of 
bupropion and naltrexone.
Another study in mice27 explored the use of bupropion/
naltrexone associated with amylin. The combination therapy 
exerted additive effects to reduce cumulative food intake, 
body weight, and fat mass. The experiment was performed 
with pair-fed animals, which were mice with the same calo-
rie intake as those treated with bupropion/naltrexone and 
amylin. Both groups showed a similar body-weight loss but 
the pharmacological treated group lost 68% more fat and 
better maintained lean mass, so this additive effect could be 
attributed to the pharmacological effect and not to calorie 
restriction.
Major clinical trials
The major clinical trials are summarized in Table 2. The first 
human trial of this combination for the treatment of obesity 
was performed in the first Phase II clinical trial conducted in 
2004 and published in 2008.30 Two hundred and thirty eight 
subjects with a BMI between 30 and 40 kg/m2 were blindly 
randomized to one among four treatment groups: placebo (P), 
bupropion SR 300 mg/day (B), naltrexone immediate release 
50 mg/day (N), or the combination of bupropion plus nal-
trexone (B + N). The primary endpoint was the percentage 
body-weight reduction at week 16, and, for patients in groups 
B and B + N, there was an extension period to week 24. At 
week 16, the adjusted percentage of body-weight change, con-
sidering an intention-to-treat (ITT) analysis, was -1.0, -2.0, 
-3.6, and -4.0 kg for the P, N, B and B + N groups, respec-
tively (P,0.001). In those patients who completed the overall 
protocol (n=146), the adjusted percentage of body-weight 
change difference between the P and B + N groups was more 
pronounced (-1.0 vs -4.8; P,0.001). In the extension phase, 
at week 24, the adjusted percentage of body-weight change, 
with an ITT analysis, was -4.0 versus -5.2 for the B and B + 
N groups, respectively (P nonsignificant). In the completers 
group (n=59), the unadjusted percentage of body-weight 
Table 2 Major clinical trials assessing bupropion plus naltrexone as obesity treatment
Trial phase Publication Subjects Placebo-subtracted weight loss Safety
ii Greenway et al28 n=238 
BMi 30–40 kg/m2
week 16 (iTT analysis): -3.00% No SAes 
Ae: nausea
ii Greenway et al31 n=419 
BMi 30–40 kg/m2
week 24 (iTT analysis): -4.65%  
(with bupropion SR 400 mg/day  
plus naltrexone immediate  
release 32 mg/day)
One possibly drug-related SAe  
(atrial fibrillation)
Aes: nausea, headache,  
dizziness
iii Greenway et al36 
COR-i
n=1,742 
Uncomplicated BMi 30–45 kg/m2  
or BMi 27–45 kg/m2 plus  
dyslipidemia or hypertension
Duration 56 weeks but only 50.00%  
of patients completed the study 
Primary analysis: -4.80%  
(with bupropion 360 mg plus  
naltrexone SR 32 mg/day)
No SAes related to investigational 
drug 
Aes: nausea, headache, constipation
iii wadden et al46 
COR-BMOD
n=793 
Uncomplicated BMi 30–45 kg/m2  
or BMi 27–45 kg/m2 plus  
dyslipidemia or hypertension
week 56 (iTT analysis): -4.20% 
 (with BMOD plus a combination  
of naltrexone SR 32 mg/day  
and bupropion 360 mg/day)
Two possibly drug-related  
SAes (cholecystitis) 
Aes: nausea, constipation,  
dizziness, dry mouth, tremor,  
abdominal pain, tinnitus
iii Apovian et al48 
COR-ii
n=1,496 
Uncomplicated BMi 30–45 kg/m2  
or BMi 27–45 kg/m2 plus  
dyslipidemia or hypertension
week 28 (iTT analysis): -4.60%  
(with bupropion 360 mg/day plus  
naltrexone SR 32 mg/day)
2.1% of patients in NB32  
group had an SAe,  
including one episode  
of seizures and one myocardial 
infarction 
Aes: nausea, headache, constipation
Abbreviations: AE, adverse event; BMI, body mass index; BMOD, behavior-modification program; COR-I, Contrave Obesity Research I; COR-II, Contrave Obesity 
Research II; COR-BMOD, Contrave Obesity Research and Behaviour Modification; ITT, intention to treat; NB32, naltrexone SR 32 mg/day plus bupropion 360 mg/day; 
SAe, serious adverse event; SR, sustained-release.





change was -4.0 versus -6.5 for the B and B + N groups, 
respectively (P,0.05). Thus, a sustained weight reduction, 
without evidence of an efficacy plateau, was observed with 
the combination of B + N. Completers of B + N diverged 
from P and N groups at week 16 and from B group at week 
24. Regarding safety endpoints, there were no drug-related 
serious adverse effects and the most common reported adverse 
event (AE) was nausea with an incidence of 34.5% in group 
N, 31.4% in group B + N, and 1.9% in group P.
A second Phase II clinical trial, especially focused on 
finding the optimal naltrexone dose, was conducted between 
2005 and 2006 and published in 2009.31 Four hundred and 
nineteen patients with a BMI between 30 and 40 kg/m2 
participated in this study. They were blinded randomized 
to placebo (P), bupropion SR 400 mg/day (B), naltrex-
one immediate release 48 mg/day (N48), bupropion SR 
400 mg/day plus naltrexone immediate release 16 mg/day 
(NB16), bupropion SR 400 mg/day plus naltrexone immedi-
ate release 32 mg/day (NB32) and bupropion 400 mg/day 
plus naltrexone immediate release 48 mg/day (NB48). 
The primary endpoint was the percentage of weight loss at 
week 24, and the ITT analysis showed a placebo- subtracted 
weight loss of -4.62% for NB16, -4.65% for NB32 
and -3.53% for NB48 (P,0.001). Weight loss was also 
significantly greater with all combinations of bupropion 
and naltrexone versus monotherapy, with the exception of 
B versus NB48. There was a high attrition rate, mainly due 
to nausea, in the group of NB48 (only 37% completed the 
24 weeks of treatment), which clearly limited its effective-
ness according to the ITT analysis. In the extension study, 
at week 48, the percentages of weight loss were -2.7% for 
B, -5.5 for NB16, -6.6% for NB32 and -5.0 for NB48 
(P,0.05). Regarding safety endpoints, there were eight 
serious adverse events (SAEs) during the 48 weeks. Only 
one, a case of atrial fibrillation, was felt to be possibly related 
to the study drug by the investigator. The most common 
adverse effect was nausea, which was clearly related to the 
dose of naltrexone. The incidence of this effect reached 41% 
in the NB48 group.
Orexigen Therapeutics, developer of the commercial brand 
Contrave (bupropion plus naltrexone SR), started a Phase 
III research program called “Contrave Obesity Research” 
(COR). The COR-I study, the first of the program, was con-
ducted between 2007 and 2009 and published in 2010.36 The 
participating subjects had either uncomplicated obesity with 
a BMI between 30 and 45 kg/m2 or a BMI of 27–45 kg/m2 
associated with dyslipidemia or arterial hypertension. A total 
of 1,742 patients were randomized into one of the three 
treatment groups: bupropion 360 mg plus naltrexone SR 
32 mg/day (NB32), bupropion 360 mg plus naltrexone SR 
16 mg/day (NB16), or placebo (P). The primary endpoints 
were the percentage of weight loss and the proportion of 
patients achieving a weight loss of 5% or greater. Only 
50% completed the 56 weeks of treatment. The primary 
analysis included all randomized patients with a post-baseline 
weight measurement (n=1,453). The percentage of weight 
loss was -1.3% in the P group, -5.0% in the NB16 group, 
and -6.1% in the NB32 group (P,0.001). There were nine 
SAEs in the NB32 group, nine in the NB16 group, and eight 
in the P group. None of them was related to the investigational 
drug according to the researcher’s reports. The most frequently 
reported AE was nausea, with an incidence of 29.8% in the 
two NB groups combined, in front of 5.3% in the P group.
Another Phase III study in the COR program was published 
in 2011.46 In this trial, the pharmacological intervention was 
carried out together with an intensive behavior-modification 
program (BMOD), following the recommendation of an expert 
panel of the National Institutes of Health.4 Patients (n=793) 
with an uncomplicated obesity (BMI between 30 and 45 kg/m2) 
or with a BMI between 27 and 45 kg/m2 plus dyslipidemia 
or hypertension were randomized at a 1:3 ratio to BMOD 
plus placebo or BMOD plus a combination of naltrexone 
SR 32 mg/day and bupropion 360 mg/day (NB32). The co-
primary endpoints were percentage of change in weight and 
the proportion of participants who lost $5% of the baseline 
weight at week 56. With an ITT analysis, at week 56, weight 
loss was 5.1% with placebo plus BMOD versus 9.3% with 
NB32 + BMOD (P,0.001). Completers analysis revealed 
weight losses of 7.3% (n=106) versus 11.5% (n=301), 
respectively (P,0.001). There were two SAEs potentially 
related to the study drug, consisting of cholecystitis. The most 
common adverse effect was nausea (incidence of 34% in the 
NB32 group). Other adverse effects that were more frequently 
reported in the NB32 group were constipation, dizziness, dry 
mouth, tremor, abdominal pain, and tinnitus.
The COR-II48 study had a very similar design to COR-I, 
but it had only two treatment arms: placebo versus bupro-
pion 360 mg/day plus naltrexone SR 32 mg/day (NB32) in a 
1:2 proportion. It was conducted between December 2007 and 
June 2009 and published in 2013. A total of 1,496 subjects 
with uncomplicated obesity (BMI 30–45 kg/m2) or with a 
BMI between 27 and 45 kg/m2 with concomitant hypertension 
or dyslipidemia took part in this double-blind placebo-con-
trolled trial. The co-primary endpoints were the percent-
age of weight change and the proportion achieving a 5% 
weight loss at week 28. A greater weight loss was observed 
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with NB32 versus placebo at week 28 (-6.5% vs -1.9%; 
P,0.001). There was an extension to 56 weeks, and patients 
who had not achieved a weight loss greater than 5% by week 
28 were re-randomized to NB32 or bupropion 360 mg/day 
plus naltrexone SR 48 mg/day. There were no significant dif-
ferences between these groups. Regarding safety, there was 
an SAE in 2.1% of patients in the NB32 group, including 
one episode of seizures and one of myocardial infarction, in 
front of 1.4% of patients with an SAE in the placebo group. 
The most frequent AEs related to the treatment were nausea, 
headache, and constipation.
Regarding other endpoints, which have mainly been 
focused on cardiovascular risk markers, the overall effect of 
the naltrexone/bupropion combination has been positive over 
lipid profile and insulin resistance. In the COR-II study,48 at 
week 28, change in low-density lipoprotein was -4.4  versus 
0.0 mg/dL, change in triglycerides was -7.3% versus -1.4%, 
change in high-density lipoprotein (HDL) was +1.2 versus -1.4 
mg/dL, and change in homeostatic model assessment-insulin 
resistance index was -16.4% versus -4.2% for NB32 versus 
placebo, respectively. In a Phase II sub-study, approximately 
78% of weight loss with the combination was due to loss 
of adipose tissue, and the proportion of subcutaneous and 
visceral adiposity loss was similar at week 24.47 This is com-
parable to the pattern of weight loss accomplished with diet 
and exercise.
However, these positive effects were not observed for blood 
pressure. In the COR-II study,48 at week 28, change in systolic 
blood pressure was -0.9 versus -1.2 mmHg (P=0.055) and 
change in diastolic blood pressure was +0.2 versus -0.7 mmHg 
(P,0.05) for NB32 versus placebo, respectively. Heart rate was 
also increased by an average of 1 bpm in the NB group. How-
ever, the normal 24-hour circadian patterns of blood pressure 
and heart rate were maintained over 1 year of treatment.43 These 
findings are consistent with the well-known pharmacological 
effects of bupropion on blood pressure and heart rate, but we 
need more information on cardiovascular outcomes.35
A Phase III trial called “Light Study”,66 which has the aim 
of assessing the cardiovascular outcomes of the combination 
of bupropion and naltrexone in the treatment of obesity, is 
ongoing and the primary completion date is estimated to be 
2017. However, a provisional analysis of the data might be 
performed by the end of 2014.
Human studies in different  
clinical situations
A clinical trial assessing the efficacy of bupropion and 
naltrexone in smoking cessation and weight changes in 
overweight and obese smoking subjects was published 
in 2010.32 Thirty patients were enrolled in the open-label 
and single-arm study of 24 weeks and were treated with 
naltrexone SR 32 mg/day and bupropion SR 360 mg/day. 
The abstinence rate achieved was 48%, and patients who 
continued smoking significantly reduced their nicotine dose. 
Body weight was essentially unchanged (week 12: -0.1%; 
week 24: +0.4%). The absence of the typical weight gain 
associated with smoking cessation should be considered a 
significant advance.
A clinical trial assessing the efficacy of bupropion and 
naltrexone in depressive symptoms and body-weight changes 
in overweight or obese patients with major depressive dis-
order was published in 2013.49 Female patients (n=25) were 
enrolled in the open-label single-arm study of 24 weeks 
and treated with naltrexone SR 32 mg/day and bupropion 
SR 360 mg/day. A significant improvement in Montgomery–
Åsberg Depression Rating Scale score was observed and 
body-weight losses of -4.0% at week 12 and -5.3% at week 
24 were shown using an ITT analysis.
Conclusion
Contrave®, a combination of bupropion and naltrexone SR, 
seems an interesting drug to reduce appetite and therefore 
induce weight loss. The mechanism of action of both drugs in 
combination is synergistic or at least fully additive and more 
effective than in monotherapy. We can conclude from the cur-
rent published reports that the effectiveness of bupropion plus 
naltrexone in the treatment of obesity is moderate. However, 
a weight loss of at least 5% was achieved in all the studies 
and minimal side effects were observed (mainly nausea). 
This weight reduction is similar to that achieved with other 
drugs approved for the treatment of obesity such as orlistat 
and sibutramine. Regarding effects other than weight loss, 
the combination has a positive effect on all components 
of the lipid profile (low-density lipoprotein, high-density 
lipoprotein, triglycerides) and insulin resistance. However, 
the lack of effect on blood pressure and the increase in heart 
rate of 1 bpm caused the authorities to postpone its approval. 
We are waiting for the results of the ongoing trial about car-
diovascular outcomes that will be finished by 2017. In our 
opinion, given the scarcity of drugs for obesity treatment and 
considering the benefits of a 5% weight loss and benefits on 
the lipid profile, we wish for a favorable resolution on the 
cardiovascular outcomes of this combined drug.
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